Barclays Initiates Biogen Idec At Overweight

Analysts at Barclays initiated coverage on shares of

with a Overweight rating. The target price for Biogen Idec is set to $425. Biogen Idec shares have surged 23.11% over the past 52 weeks, while the S&P 500 index has gained 9.94% in the same period. Biogen Idec's shares fell 1.54% to close at $336.74 yesterday.